NDATRANSDERMALSYSTEM
Approved
Feb 2020
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
8
Data completeness
4/8 — Partial
TWIRLA (levonorgestrel/ethinyl estradiol) by Agile Therapeutics is estrogen receptor agonists [moa]. First approved in 2020.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TWIRLA is a transdermal contraceptive patch combining levonorgestrel and ethinyl estradiol, acting as an estrogen receptor agonist to prevent ovulation. It provides continuous hormonal delivery via skin application, offering an alternative to oral contraceptives for women seeking pregnancy prevention.
LOE Approaching1.9 years to LOE
With LOE approaching in 2028, the brand team is transitioning from growth initiatives toward lifecycle management and defensive positioning against generic entrants and established competitors.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
Started May 2024
24 enrolled
Healthy Participants
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Started Jan 2024
60 enrolled
Healthy Participants
A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
Started Oct 2021
28 enrolled
Residual Drug Amount of EE and LNG
A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
Started Jun 2018
14 enrolled
Healthy
Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
Started Jul 2012
36 enrolled
Healthy
Worked on TWIRLA at Agile Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.